Guangzhou Anbiping Pharmaceutical Technology

Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. (stock code: 688393) is a high-tech enterprise established in 2005 that specializes in in-vitro diagnostic products. The company focuses on the research and development, production, and sale of reagents and instruments for tumor screening and precision diagnosis, primarily for pathology departments. It was founded by Cai Xiangting, who currently serves as the chairman and general manager. Mr. Cai, born in 1964, has a background in preventive medicine and extensive experience in the pharmaceutical and medical technology sectors before establishing the company.

The company has established a comprehensive set of technology platforms including liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH). This allows them to meet a wide range of clinical needs, from observing cell morphology to detecting protein expression and genetic markers. Their product portfolio is one of the most extensive in China's domestic pathology diagnosis market, with some products receiving CE, BSI, and Japanese Ministry of Health, Labour and Welfare certifications. The business operates on a dual model of providing both products and services, serving nearly 3,000 medical institutions across China, including over 1,300 tertiary hospitals. In August 2020, the company was listed on the Shanghai Stock Exchange's STAR MARKET.

Guangzhou Anbiping has strategically focused on advancing pathology departments through what it terms the "Four Modernizations": automation, standardization, digitization, and intelligence. This strategy is supported by a full industrial chain that includes biological raw materials, pathology products, digital and intelligent software, and services to enhance pathological capabilities. The company has also expanded into digital and AI-powered pathology, developing AI-assisted diagnostic tools to improve efficiency and accuracy for pathologists. This includes the development of a pathological medical image analysis and processing software, which has obtained a Class II medical device license.

Keywords: pathological diagnosis, in-vitro diagnostics, tumor screening, precision diagnosis, liquid-based cytology, PCR, immunohistochemistry, fluorescence in situ hybridization, medical diagnostic instruments, cancer diagnostics, pathology automation, digital pathology, AI diagnostics, molecular diagnostics, CE certification, medical reagents, cell pathology, genetic testing, healthcare technology, clinical diagnostics